News Releases

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference
BURLINGTON, Mass. , May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million , despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents o f  $58.4 million Company to host investor conference call and webcast today, Tuesday, May 14 ,[…]
scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
BURLINGTON, Mass. , May 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass. , May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care,[…]
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass. , April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc.[…]
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Generated 4Q 2023 net FUROSCIX ® revenue of $6.1 million , at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year net FUROSCIX ® revenue of $13.6 million , at the upper end of the range provided in January Ended[…]
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass. , March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient[…]
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
BURLINGTON, Mass. , Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue
Company anticipates Q4 2023 net FUROSCIX   revenue to be approximately $5.9 to $6.1 million ; full-year net FUROSCIX revenue of approximately $13.4 to $13.6 million Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4 Inventory levels at the end of Q4 2023 consistent[…]